Answers are grounded in this paper and cite their sources.
Clinical observations reveal that tailored therapy for prostate cancer is vital in hypogonadism due to prolactinoma, suggesting careful monitoring is essential.
Patients with prolactinoma-induced hypogonadism remain at risk for PCa. Dopamine agonists for treatment of prolactinoma may worsen PCa due to testosterone rebound; GnRH agonists for treatment of PCa may precipitate pituitary apoplexy in patients with preexisting pituitary adenoma. GnRH antagonists may be a theoretically safer alternative. Cautious and tailored selection of therapy alongside close clinical monitoring are essential to optimize care of this complex patient population.
No takes yet. Share an insight, caveat, or question.
Seibert et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: